Nomination Committee appointed for the Annual General Meeting 2021

The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Wednesday 28 April 2021 at the company’s headoffice in Botkyrka, has been appoined.

The Nomination Committee for the 2021 AGM in Bactiguard Holding AB (publ) will consist of the following members:

Helena Borglund, appointed by KK Invest AB
Thomas von Koch, appointed by Bactiguard B.V.
Mats J Andersson, appointed by Nordea Fonder
Jan Ståhlberg, appointed by Jan Ståhlberg
Per Colleen, appointed by Fjärde AP Fonden

The Chairman of the Board of Directors, Christian Kinch, will be adjourned to the Nominaction Committee but without voting rights.

In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of five members. The Chairman of the Board of Directors shall contact the largest shareholders of the company, in terms of voting power, pursuant to Euroclear Sweden AB’s print out of the share register on 31 August. Each of the largest shareholders shall be offered the opportunity to, within reasonable time, appoint a member.

The Nomination Committee will make proposals to the AGM 2021 concerning the election of a chairman for the AGM, the chairman and other members of the Board of Directors, as well as auditors. The Nomination Committee will also make proposals regarding remuneration to the Board of Directors, including any separate remuneration for committee work, as well as remuneration to the auditors. Further, the Nomination Committee will make a proposal regarding principles for forming the Nomination Committee for the AGM in 2022.

Shareholders who wish to make proposals to the Nomination Committee can do so by writing to the Nomination Committee under the following address:

Nomination Committee
Bactiguard Holding AB (publ)
Box 15
146 21 Tullinge

Proposals can also be sent by email to the following address: valberedningen@bactiguard.com

In order for the Nomination Committee to be able to address proposals in a constructive manner, they should have been received by 17 January, 2021.

The proposals of the Nomination Committee will be presented in the invitation to the AGM and at the company’s website.

 

For further information, please contact:
Gabriella Björknert Caracciolo, CFO and deputy CEO, mobile: +46 72 141 62 49

 

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. In this way, we save significant costs for healthcare and society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through license agreements and with our BIP (Bactiguard Infection Protection) portfolio of products. Through our license partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.

Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.

Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com

About Us

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com